Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Withdrawn 2Unknown 1Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 30Myelodysplastic Syndromes 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Leukemia 17Multiple Myeloma 13Lymphoma, Non-Hodgkin 13Leukemia, Myelogenous, Chronic, BCR-ABL Positive 12Leukemia, Lymphocytic, Chronic, B-Cell 12Lymphoma 11Hodgkin Disease 11Myeloproliferative Disorders 9Congenital Abnormalities 9Neoplasms, Plasma Cell 8Leukemia, Myeloid, Accelerated Phase 8Blast Crisis 8Lymphoma, Large B-Cell, Diffuse 7Lymphoma, Follicular 7Leukemia, Myelomonocytic, Chronic 7Leukemia, Myeloid, Chronic-Phase 7Primary Myelofibrosis 6Myelodysplastic-Myeloproliferative Diseases 6Lymphoma, Mantle-Cell 6Lymphoma, B-Cell, Marginal Zone 6Leukemia, Myelomonocytic, Juvenile 6Lymphoma, Large-Cell, Immunoblastic 5Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 5Hematologic Neoplasms 5Graft vs Host Disease 5Burkitt Lymphoma 5Sezary Syndrome 4

Interventions

Cyclophosphamide 4Prednisone 3Lenalidomide 3fludarabine phosphate 2etoposide phosphate 2cobomarsen 2Whole-Body Irradiation 2Vorinostat 2Vincristine 2Stem Cell Transplantation 2Nivolumab 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Etoposide 2Doxorubicin 2Bortezomib 2Alemtuzumab 2tazemetostat 1sargramostim 1romidepsin 1poly ICLC 1plerixafor 1pegylated granulocyte colony-stimulating factor, human 1pegfilgrastim 1pegaspargase 1liposomal doxorubicin 1forodesine 1fludarabine 1duvelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, T-Cell × Busulfan × Clear all
NCT01746173 2023-01-30

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Terminated
5 enrolled 7 charts
Lymphoid

Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡